AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
The Drug Discovery World Podcast
Exploring the potential of a new class of drug candidates
Mar 12, 2024
Exploring the potential of a new class of drug candidates with Vicore Pharma's CEO, focusing on angiotensin II type 2 receptor agonists for treating rare respiratory diseases. Discussions on technology, collaboration, challenges in addressing idiopathic pulmonary fibrosis, and opportunities in drug development in Sweden.
14:06
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Vycor Pharma focuses on developing drugs that activate the AT2 receptor in the angiotensin II pathway to target rare respiratory diseases like idiopathic pulmonary fibrosis.
- Compared to many cancers, idiopathic pulmonary fibrosis patients have a grim prognosis, emphasizing the urgent need for new treatment options like those developed by Vycor Pharma.
Deep dives
Vycor Pharma's Approach and Pipeline Focus
Vycor Pharma focuses on developing drugs that activate the AT2 receptor in the angiotensin II pathway. Initially targeting rare respiratory diseases like idiopathic pulmonary fibrosis, Vycor aims to harness a natural tissue repair system. They have generated promising clinical data in this area and are exploring digital therapies to support patients with pulmonary fibrosis.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode